Human Nasal Inferior Turbinate-Derived Neural Stem Cells Improve the Niche of Substantia Nigra Par Compacta in a Parkinson's Disease Model by Modulating Hippo Signaling.
Cell-based therapy
Human nasal turbinate derived stem cells
Niche control
Parkinson’s disease
Regenerative medicine
Journal
Tissue engineering and regenerative medicine
ISSN: 2212-5469
Titre abrégé: Tissue Eng Regen Med
Pays: Korea (South)
ID NLM: 101699923
Informations de publication
Date de publication:
10 Apr 2024
10 Apr 2024
Historique:
received:
03
11
2023
accepted:
15
02
2024
revised:
30
01
2024
medline:
11
4
2024
pubmed:
11
4
2024
entrez:
10
4
2024
Statut:
aheadofprint
Résumé
Parkinson's disease (PD) is one of the most prevalent neurodegenerative diseases, following Alzheimer's disease. The onset of PD is characterized by the loss of dopaminergic neurons in the substantia nigra. Stem cell therapy has great potential for the treatment of neurodegenerative diseases, and human nasal turbinate-derived stem cells (hNTSCs) have been found to share some characteristics with mesenchymal stem cells. Although the Hippo signaling pathway was originally thought to regulate cell size in organs, recent studies have shown that it can also control inflammation in neural cells. Dopaminergic neuron-like cells were differentiated from SH-SY5Y cells (DA-Like cells) and treated with 1-Methyl-4-phenylpyridinium iodide to stimulate Reactive oxidative species (ROS) production. A transwell assay was conducted to validate the effect of hNTSCs on the Hippo pathway. We generated an MPTP-induced PD mouse model and transplanted hNTSCs into the substantia nigra of PD mice via stereotaxic surgery. After five weeks of behavioral testing, the brain samples were validated by immunoblotting and immunostaining to confirm the niche control of hNTSCs. In-vitro experiments showed that hNTSCs significantly increased cell survival and exerted anti-inflammatory effects by controlling ROS-mediated ER stress and hippocampal signaling pathway factors. Similarly, the in-vivo experiments demonstrated an increase in anti-inflammatory effects and cell survival rate. After transplantation of hNTSCs, the PD mouse model showed improved mobility and relief from PD symptoms. hNTSCs improved the survival rate of dopaminergic neurons by manipulating the hippocampal pathway through Yes-associated protein (YAP)/transcriptional coactivator with a PDZ-binding motif (TAZ) by reducing inflammatory cytokines. In this study, we found that controlling the niche of hNTSCs had a therapeutic effect on PD lesions.
Sections du résumé
BACKGROUND
BACKGROUND
Parkinson's disease (PD) is one of the most prevalent neurodegenerative diseases, following Alzheimer's disease. The onset of PD is characterized by the loss of dopaminergic neurons in the substantia nigra. Stem cell therapy has great potential for the treatment of neurodegenerative diseases, and human nasal turbinate-derived stem cells (hNTSCs) have been found to share some characteristics with mesenchymal stem cells. Although the Hippo signaling pathway was originally thought to regulate cell size in organs, recent studies have shown that it can also control inflammation in neural cells.
METHODS
METHODS
Dopaminergic neuron-like cells were differentiated from SH-SY5Y cells (DA-Like cells) and treated with 1-Methyl-4-phenylpyridinium iodide to stimulate Reactive oxidative species (ROS) production. A transwell assay was conducted to validate the effect of hNTSCs on the Hippo pathway. We generated an MPTP-induced PD mouse model and transplanted hNTSCs into the substantia nigra of PD mice via stereotaxic surgery. After five weeks of behavioral testing, the brain samples were validated by immunoblotting and immunostaining to confirm the niche control of hNTSCs.
RESULTS
RESULTS
In-vitro experiments showed that hNTSCs significantly increased cell survival and exerted anti-inflammatory effects by controlling ROS-mediated ER stress and hippocampal signaling pathway factors. Similarly, the in-vivo experiments demonstrated an increase in anti-inflammatory effects and cell survival rate. After transplantation of hNTSCs, the PD mouse model showed improved mobility and relief from PD symptoms.
CONCLUSION
CONCLUSIONS
hNTSCs improved the survival rate of dopaminergic neurons by manipulating the hippocampal pathway through Yes-associated protein (YAP)/transcriptional coactivator with a PDZ-binding motif (TAZ) by reducing inflammatory cytokines. In this study, we found that controlling the niche of hNTSCs had a therapeutic effect on PD lesions.
Identifiants
pubmed: 38600296
doi: 10.1007/s13770-024-00635-3
pii: 10.1007/s13770-024-00635-3
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Ministry of Science and ICT, South Korea
ID : 2021M3F7A1083232
Organisme : Korean Fund for Regenerative Medicine
ID : 23C0121L1
Informations de copyright
© 2024. The Author(s).
Références
Bloem BR, Okun MS, Klein C. Parkinson’s disease. The Lancet. 2021;397:2284–303.
doi: 10.1016/S0140-6736(21)00218-X
Sveinbjornsdottir S. The clinical symptoms of Parkinson’s disease. J Neurochem. 2016;139:318–24.
doi: 10.1111/jnc.13691
pubmed: 27401947
Wakabayashi K, Tanji K, Odagiri S, Miki Y, Mori F, Takahashi H. The Lewy body in Parkinson’s disease and related neurodegenerative disorders. Mol Neurobiol. 2013;47:495–508.
doi: 10.1007/s12035-012-8280-y
pubmed: 22622968
Spillantini MG, Goedert M. The α-synucleinopathies: Parkinson’s disease, dementia with lewy bodies, and multiple system atrophy. Ann N Y Acad Sci. 2000;920:16–27.
doi: 10.1111/j.1749-6632.2000.tb06900.x
pubmed: 11193145
Bendor JT, Logan TP, Edwards RH. The function of α-synuclein. Neuron. 2013;79:1044–66.
doi: 10.1016/j.neuron.2013.09.004
pubmed: 24050397
Thorne NJ, Tumbarello DA. The relationship of alpha-synuclein to mitochondrial dynamics and quality control. Front Mol Neurosci. 2022;15:947191.
doi: 10.3389/fnmol.2022.947191
pubmed: 36090250
pmcid: 9462662
Park JH, Burgess JD, Faroqi AH, DeMeo NN, Fiesel FC, Springer W, et al. Alpha-synuclein-induced mitochondrial dysfunction is mediated via a sirtuin 3-dependent pathway. Mol Neurodegener. 2020;15:5.
doi: 10.1186/s13024-019-0349-x
pubmed: 31931835
pmcid: 6956494
Risiglione P, Zinghirino F, Di Rosa MC, Magrì A, Messina A. Alpha-synuclein and mitochondrial dysfunction in Parkinson’s disease: the emerging role of VDAC. Biomolecules. 2021;11:718.
doi: 10.3390/biom11050718
pubmed: 34064816
pmcid: 8170894
Lin KJ, Lin KL, Chen SD, Liou CW, Chuang YC, Lin HY, et al. The overcrowded crossroads: mitochondria, alpha-synuclein, and the endo-lysosomal system interaction in Parkinson’s disease. Int J Mol Sci. 2019;20:5312.
doi: 10.3390/ijms20215312
pubmed: 31731450
pmcid: 6862467
Ganjam GK, Bolte K, Matschke LA, Neitemeier S, Dolga AM, Höllerhage M, et al. Mitochondrial damage by α-synuclein causes cell death in human dopaminergic neurons. Cell Death Dis. 2019;10:865.
doi: 10.1038/s41419-019-2091-2
pubmed: 31727879
pmcid: 6856124
Puspita L, Chung SY, Shim JW. Oxidative stress and cellular pathologies in Parkinson’s disease. Mol Brain. 2017;10:53.
doi: 10.1186/s13041-017-0340-9
pubmed: 29183391
pmcid: 5706368
Tripathi T, Chattopadhyay K. Interaction of α-synuclein with ATP synthase: switching role from physiological to pathological. ACS Chem Neurosci. 2019;10:16–7.
doi: 10.1021/acschemneuro.8b00407
pubmed: 30133256
Fernández-Checa JC, Fernández A, Morales A, Marí M, García-Ruiz C, Colell A. Oxidative stress and altered mitochondrial function in neurodegenerative diseases: lessons from mouse models. CNS Neurol Disord Drug Targets. 2010;9:439–54.
doi: 10.2174/187152710791556113
pubmed: 20522012
Wang J, Fröhlich H, Torres FB, Silva RL, Poschet G, Agarwal A, et al. Mitochondrial dysfunction and oxidative stress contribute to cognitive and motor impairment in FOXP1 syndrome. Proc Natl Acad Sci U S A. 2022;119:e2112852119.
doi: 10.1073/pnas.2112852119
pubmed: 35165191
pmcid: 8872729
Pozo Devoto VM, Falzone TL. Mitochondrial dynamics in Parkinson’s disease: a role for α-synuclein? Dis Model Mech. 2017;10:1075–87.
doi: 10.1242/dmm.026294
pubmed: 28883016
pmcid: 5611962
Angelova PR, Abramov AY. Role of mitochondrial ROS in the brain: from physiology to neurodegeneration. FEBS Lett. 2018;592:692–702.
doi: 10.1002/1873-3468.12964
pubmed: 29292494
Liu XL, Wang YD, Yu XM, Li DW, Li GR. Mitochondria-mediated damage to dopaminergic neurons in Parkinson’s disease. Int J Mol Med. 2018;41:615–23.
pubmed: 29207041
Devi L, Raghavendran V, Prabhu BM, Avadhani NG, Anandatheerthavarada HK. Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain. J Biol Chem. 2008;283:9089–100.
doi: 10.1074/jbc.M710012200
pubmed: 18245082
pmcid: 2431021
Wei X, Huang G, Liu J, Ge J, Zhang W, Mei Z. An update on the role of Hippo signaling pathway in ischemia-associated central nervous system diseases. Biomed Pharmacother. 2023;162:114619.
doi: 10.1016/j.biopha.2023.114619
pubmed: 37004330
Sahu MR, Mondal AC. The emerging role of Hippo signaling in neurodegeneration. J Neurosci Res. 2020;98:796–814.
doi: 10.1002/jnr.24551
pubmed: 31705587
Sahu MR, Mondal AC. Neuronal Hippo signaling: from development to diseases. Dev Neurobiol. 2021;81:92–109.
doi: 10.1002/dneu.22796
pubmed: 33275833
Li X, Li K, Chen Y, Fang F. The role of Hippo signaling pathway in the development of the nervous system. Dev Neurosci. 2021;43:63–70.
doi: 10.1159/000515633
Hindley CJ, Condurat AL, Menon V, Thomas R, Azmitia LM, Davis JA, et al. The Hippo pathway member YAP enhances human neural crest cell fate and migration. Sci Rep. 2016;6:23208.
doi: 10.1038/srep23208
pubmed: 26980066
pmcid: 4793290
Cheng J, Wang S, Dong Y, Yuan Z. The role and regulatory mechanism of Hippo signaling components in the neuronal system. Front Immunol. 2020;11:281.
doi: 10.3389/fimmu.2020.00281
pubmed: 32140159
pmcid: 7042394
Ding R, Weynans K, Bossing T, Barros CS, Berger C. The Hippo signalling pathway maintains quiescence in Drosophila neural stem cells. Nat Commun. 2016;7:10510.
doi: 10.1038/ncomms10510
pubmed: 26821647
pmcid: 4740179
Wei X, Yang X, Han ZP, Qu FF, Shao L, Shi YF. Mesenchymal stem cells: a new trend for cell therapy. Acta Pharmacol Sin. 2013;34:747–54.
doi: 10.1038/aps.2013.50
pubmed: 23736003
pmcid: 4002895
Brown C, McKee C, Bakshi S, Walker K, Hakman E, Halassy S, et al. Mesenchymal stem cells: cell therapy and regeneration potential. J Tissue Eng Regen Med. 2019;13:1738–55.
doi: 10.1002/term.2914
pubmed: 31216380
Kim Y-J, Park H-J, Lee G, Bang OY, Ahn YH, Joe E, et al. Neuroprotective effects of human mesenchymal stem cells on dopaminergic neurons through anti-inflammatory action. Glia. 2009;57:13–23.
doi: 10.1002/glia.20731
pubmed: 18661552
Miao Z, Sun H, Xue Y. Isolation and characterization of human chorionic membranes mesenchymal stem cells and their neural differentiation. Tissue Eng Regen Med. 2017;14:143–51.
doi: 10.1007/s13770-017-0025-6
pubmed: 30603471
pmcid: 6171582
Zhang R, Liu Y, Yan K, Chen L, Chen XR, Li P, et al. Anti-inflammatory and immunomodulatory mechanisms of mesenchymal stem cell transplantation in experimental traumatic brain injury. J Neuroinflamm. 2013;10:871.
doi: 10.1186/1742-2094-10-106
Lim JY, In Park S, Park SA, Jeon JH, Jung HY, Yon JM, et al. Potential application of human neural crest-derived nasal turbinate stem cells for the treatment of neuropathology and impaired cognition in models of Alzheimer’s disease. Stem Cell Res Ther. 2021;12:402.
doi: 10.1186/s13287-021-02489-1
pubmed: 34256823
pmcid: 8278635
Lim JY, Lee JE, Park SA, Park SI, Yon JM, Park JA, et al. Protective effect of human-neural-crest-derived nasal turbinate stem cells against amyloid-β; neurotoxicity through inhibition of osteopontin in a human cerebral organoid model of Alzheimer’s disease. Cells. 2022;11:1029.
doi: 10.3390/cells11061029
pubmed: 35326480
pmcid: 8947560
Nivet E, Vignes M, Girard SD, Pierrisnard C, Baril N, Devèze A, et al. Engraftment of human nasal olfactory stem cells restores neuroplasticity in mice with hippocampal lesions. J Clin Invest. 2011;121:2808–20.
doi: 10.1172/JCI44489
pubmed: 21670501
pmcid: 3223823
Hodaie M, Neimat JS, Lozano AM. The dopaminergic nigrostriatal system and Parkinson’s disease: molecular events in development, disease, and cell death, and new therapeutic strategies. Neurosurgery. 2007;60:17–30.
doi: 10.1227/01.NEU.0000249209.11967.CB
pubmed: 17228250
Struzyna LA, Browne KD, Brodnik ZD, Burrell JC, Harris JP, Chen HI, et al. Tissue engineered nigrostriatal pathway for treatment of Parkinson’s disease. J Tissue Eng Regen Med. 2018;12:1702–16.
doi: 10.1002/term.2698
pubmed: 29766664
pmcid: 6416379
Osborn TM, Hallett PJ, Schumacher JM, Isacson O. Advantages and recent developments of autologous cell therapy for Parkinson’s disease patients. Front Cell Neurosci. 2020;14:58.
doi: 10.3389/fncel.2020.00058
pubmed: 32317934
pmcid: 7147334
Wenker SD, Leal MC, Farías MI, Zeng X, Pitossi FJ. Cell therapy for Parkinson’s disease: functional role of the host immune response on survival and differentiation of dopaminergic neuroblasts. Brain Res. 2016;1638:15–29.
doi: 10.1016/j.brainres.2015.06.054
pubmed: 26239914
Lopes FM, Schröder R, da Frota Jr ML, Zanotto-Filho A, Müller CB, Pires AS, et al. Comparison between proliferative and neuron-like SH-SY5Y cells as an in vitro model for Parkinson disease studies. Brain Res. 2010;1337:85–94.
doi: 10.1016/j.brainres.2010.03.102
pubmed: 20380819
Yun JW, Ahn JB, Kwon E, Ahn JH, Park HW, Heo H, et al. Behavior, PET and histology in novel regimen of MPTP marmoset model of Parkinson’s disease for long-term stem cell therapy. Tissue Eng Regen Med. 2016;13:100–9.
doi: 10.1007/s13770-015-0106-3
pubmed: 30603390
Pang S, Li J, Zhang Y, Chen J. Meta-analysis of the relationship between the APOE gene and the onset of Parkinson’s disease dementia. Parkinsons Dis. 2018;2018:9497147.
pubmed: 30405900
pmcid: 6204165